Is Hester Biosciences Ltd (HESTERBIO) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Hester Biosciences Ltd is a good quality company .

Is Hester Biosciences Ltd (HESTERBIO) undervalued or overvalued?

The key valuation ratios of Hester Biosciences Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone .

What is Hester Biosciences Ltd (HESTERBIO) share price return in the past 10 years?

Hester Biosciences Ltd share price has appreciated 10.6% annually (CAGR) over the past ten years.

Is Hester Biosciences Ltd (HESTERBIO) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Hester Biosciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Hester Biosciences Ltd (HESTERBIO)?

Company share prices are keep on changing according to the market conditions. The current trading price of Hester Biosciences Ltd (HESTERBIO) on 17-Apr-2026 16:59:59 at 16:59 is 1492.80.

What is the market cap of Hester Biosciences Ltd (HESTERBIO)?

Market capitalization is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 17-Apr-2026 at 16:59, the market cap of Hester Biosciences stood at Rs. 1269.90 Cr.

What is the P/E ratio of Hester Biosciences?

The latest standalone P/E ratio of Hester Biosciences as of 17-Apr-2026 is 35.92.

What is the P/B ratio of Hester Biosciences Ltd (HESTERBIO)?

The latest standalone P/B ratio of Hester Biosciences Ltd (HESTERBIO) as of 17-Apr-2026 is 3.54.

What is the 52-week high and low of Hester Biosciences Ltd (HESTERBIO)?

The 52-week high of Hester Biosciences Ltd (HESTERBIO) is Rs. 2347.70 and the 52-week low is Rs. 1250.95.

What is the TTM revenue of Hester Biosciences Ltd (HESTERBIO)?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Hester Biosciences is Rs. 275.10 (Cr.).

Hester Biosciences Ltd (HESTERBIO) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Hester Biosciences Ltd (HESTERBIO)
Brand: Hester Biosciences

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	21.8%	24.2%	26.3%	31.2%	19.7%	23.3%	17.3%	11.9%	9.3%	10.6%	-
Value Creation Index ⓘ	0.6	0.7	0.9	1.2	0.4	0.7	0.2	-0.2	-0.3	-0.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	101	123	135	171	169	208	219	254	285	286	275
Sales YoY Gr.	-	22.2%	9.3%	27%	-1%	23.1%	5.2%	15.8%	12.3%	0.5%	-
Adj EPS ⓘ	22.8	29.3	35.8	50.9	35.7	51.6	45.4	36.9	31.5	37.1	41.6
YoY Gr.	-	28.7%	22%	42.4%	-29.8%	44.3%	-11.9%	-18.7%	-14.6%	17.6%	-
BVPS (₹) ⓘ	117.9	143.5	171.7	210.9	238.7	279.3	315.5	343.7	367.6	398.6	421.6
Adj Net Profit ⓘ	19.4	24.9	30.4	43.3	30.4	43.9	38.6	31.4	26.8	31.6	35
Cash Flow from Ops. ⓘ	18.6	27.6	32.3	36.2	25.8	41.1	15.9	33.4	42.9	64	-
Debt/CF from Ops. ⓘ	2.1	1.4	1.3	1.1	1.9	0.4	7.7	4.9	3.1	1.6	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	12.3%	11.1%	9.3%	0.5%
Adj EPS ⓘ	5.6%	0.8%	-6.5%	17.6%
BVPSⓘ	14.5%	10.8%	8.1%	8.4%
Share Price	10.6%	-7.9%	-6.2%	-15.6%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	21	22.4	22.7	26.6	15.9	19.9	15.3	11.2	8.9	9.7	10.1
Op. Profit Mgn % ⓘ	33.4	33.4	36.8	39.7	31.1	34.7	27.6	21.5	16.4	18	19.9
Net Profit Mgn % ⓘ	19.2	20.2	22.6	25.3	18	21	17.6	12.4	9.4	11	12.9
Debt to Equity ⓘ	0.4	0.3	0.3	0.2	0.2	0.1	0.5	0.6	0.4	0.3	-
Working Cap Days ⓘ	229	217	220	208	261	245	279	292	271	252	117
Cash Conv. Cycle ⓘ	160	140	140	134	164	145	164	168	152	131	55

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 10.10%

Sales growth has been subdued in last 3 years 9.31%

Net Profit has been subdued in last 3 years -6.52%

Sales growth is not so good in last 4 quarters at -2.14%

	Standalone	Consolidated
TTM EPS (₹)	41.6	48.1
TTM Sales (₹ Cr.)	275	314
BVPS (₹) ⓘ	421.6	406.6
Reserves (₹ Cr.) ⓘ	350	337
P/BV ⓘ	3.54	3.67
PE ⓘ	35.92	31.01

From the Market
52 Week Low / High (₹)	1250.95 / 2347.70
All Time Low / High (₹)	0.25 / 3375.45
Market Cap (₹ Cr.)	1,270
Equity (₹ Cr.)	8.5
Face Value (₹)	10
Industry PE ⓘ	42.1

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	101	123	135	171	169	208	219	254	285	286
Operating Expenses ⓘ +	67	82	85	103	117	136	159	199	238	236
Manufacturing Costs	14	12	15	18	19	18	19	20	28	26
Material Costs	20	30	23	29	29	53	64	80	100	94
Employee Cost	15	18	22	27	37	33	39	48	57	55
Other Costs ⓘ	19	22	25	29	32	32	37	51	54	61
Operating Profit ⓘ	33	41	50	68	53	72	61	55	47	51
Operating Profit Margin (%)	33.1%	33.3%	36.8%	39.6%	31.1%	34.5%	27.6%	21.5%	16.4%	17.8%
Other Income ⓘ +	1	1	2	3	3	2	5	6	5	5
Exceptional Items ⓘ	0	0	0	0	0	-5	0	0	0	0
Interest ⓘ	4	3	2	4	5	4	2	6	5	5
Depreciation ⓘ	6	6	5	8	9	10	10	10	10	9
Profit Before Tax ⓘ	25	33	44	60	41	55	53	44	37	42
Tax ⓘ	6	8	13	16	10	15	14	12	10	10
Profit After Tax	19	25	31	44	31	40	40	32	27	32
PAT Margin (%)	19.1%	20.2%	22.7%	25.6%	18.4%	19.1%	18.0%	12.7%	9.5%	11.1%
Adjusted EPS (₹)	22.6	29.3	35.9	51.6	36.7	46.9	46.5	38.0	31.9	37.4
Dividend Payout Ratio (%)	18%	18%	28%	21%	18%	21%	22%	21%	19%	19%

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	100	122	146	179	203	238	268	292	313	339
Share Capital ⓘ	9	9	9	9	9	9	9	9	9	9
Reserves ⓘ	92	114	138	171	195	229	260	284	304	331
Debt +	34	36	39	32	39	4	107	141	109	80
Long Term Debt	13	19	15	11	7	3	73	83	79	51
Short Term Debt	21	18	24	21	32	2	33	57	30	29
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	6	7	8	8	14	14	11	29	30	33
Others Liabilities ⓘ	19	13	18	20	21	26	38	84	98	94
Total Liabilities ⓘ	159	178	210	240	277	282	424	546	550	546
Fixed Assets
Net Fixed Assets ⓘ +	62	61	67	101	97	87	84	108	103	105
Gross Block	105	110	121	162	167	165	171	199	204	212
Accumulated Depreciation	43	49	54	61	70	78	87	91	100	107
CWIP ⓘ	10	21	30	0	1	4	82	149	171	183
Investments ⓘ	9	9	14	28	41	44	65	65	65	65
Inventories	34	33	39	48	60	57	71	79	69	59
Trade Receivables	26	27	32	33	45	46	57	82	86	81
Cash Equivalents	5	11	12	2	5	1	2	6	5	2
Others Assets ⓘ	13	16	16	27	28	44	64	57	51	52
Total Assets ⓘ	159	178	210	240	277	282	424	546	550	546

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	19	28	32	36	26	41	16	33	43	64
PBT ⓘ	25	33	44	60	41	55	53	44	37	42
Adjustment ⓘ	9	9	7	8	12	20	12	15	13	16
Changes in Working Capital ⓘ	-10	-7	-9	-16	-16	-20	-33	-17	4	16
Tax Paid ⓘ	-6	-7	-9	-16	-11	-13	-16	-8	-11	-10
Cash Flow From Investing Activity ⓘ +	-6	-15	-26	-25	-21	-4	-111	-72	-21	-19
Capex	-6	0	-21	-12	-7	-4	-90	-73	-22	-20
Net Investments	0	0	-0	-1	-2	1	-20	0	0	0
Others ⓘ	0	-16	-5	-12	-12	-1	0	0	2	1
Cash Flow From Financing Activity ⓘ +	-12	-6	-6	-20	-1	-41	95	41	-24	-46
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-2	6	-4	-3	-1	-2	73	12	-3	-28
Interest Paid ⓘ	-4	-3	-2	-4	-4	-4	-1	-10	-13	-13
Dividend Paid ⓘ	-5	-4	-6	-10	-7	-6	-9	-9	-7	-5
Others ⓘ	-1	-4	7	-3	11	-30	32	48	-2	-1
Net Cash Flow ⓘ	1	6	-0	-9	3	-4	0	3	-2	-1

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	20.83	22.43	22.79	26.94	16.33	18.11	15.62	11.53	8.98	9.77
ROCE (%)	21.79	24.16	26.28	31.15	19.74	23.28	17.31	11.91	9.26	10.59
Asset Turnover Ratio	0.69	0.74	0.7	0.76	0.65	0.75	0.63	0.53	0.52	0.52
PAT to CFO Conversion(x)	1	1.12	1.03	0.82	0.84	1.03	0.4	1.03	1.59	2
Working Capital Days
Receivable Days	78	77	79	69	83	79	85	99	108	106
Inventory Days	111	97	97	93	117	103	105	107	94	81
Payable Days	97	81	120	99	135	94	72	91	107	121

About Hester Biosciences Ltd

Hester Biosciences was incorporated on April 29, 1987 as a Private Limited Company by the name of Hester Pharmaceuticals Limited. It was subsequently converted into a Public Limited Company on November 1, 1993. The company is engaged in the manufacturing of poultry vaccines. The company has been promoted by Rajiv D. Gandhi his brother Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. The company changed its name to the present in 2008.

The company is a 100% biotech company producing animal biologicals. Located near the city of Ahmedabad, in the state of Gujarat, in Western India, Hester has a state-of-the-art facility to produce live and killed (Inactivated) veterinary vaccines.

Production procedures for poultry vaccines based on in-house advanced capabilities are being followed in the areas of virus propagation in specific pathogen-free embryos, tissue culture, batch fermentation of bacteria, lyophilisation and emulsion preparation.

Hester on December 22, 2008 launched a poultry vaccine against Coryza disease in chicken, containing 3 serotypes â€“ A, B & C.

Hester is the first company in India to manufacture the Coryza vaccine with 3 strains as against other companies manufacturing the vaccine with only 2 serotypes - A & C. Coryza disease is of economical importance to poultry farmers as it causes a drop in egg production in laying birds.

Hester currently manufactures 39 types of poultry vaccines against various poultry diseases.

Product range of the company includes:

Live Vaccines
Killed Vaccines
Diagnostic kits & Seromonitoring services

Achievements/ recognition:

GMP and ISO 9001:2000 certified company

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Hester Biosciences Ltd (HESTERBIO) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Hester Biosciences Share Price